Causal Relationships of Circulating Inflammatory Proteins and Portal Vein Thrombosis: A Mendelian Randomization Study

IF 3.6 2区 医学 Q2 HEMATOLOGY Seminars in thrombosis and hemostasis Pub Date : 2024-09-18 DOI:10.1055/s-0044-1790259
Bihui Zhang, Ziping Yao, Pengyu Li, Guochen Niu, Ziguang Yan, Kang She, Gong Cheng, Min Yang
{"title":"Causal Relationships of Circulating Inflammatory Proteins and Portal Vein Thrombosis: A Mendelian Randomization Study","authors":"Bihui Zhang, Ziping Yao, Pengyu Li, Guochen Niu, Ziguang Yan, Kang She, Gong Cheng, Min Yang","doi":"10.1055/s-0044-1790259","DOIUrl":null,"url":null,"abstract":"<p>Portal vein thrombosis (PVT) is commonly encountered in patients with cirrhosis, challenging our understanding of its development, particularly the ambiguous contribution of inflammation. This study utilized Mendelian randomization (MR) to explore the causal impact of circulating inflammatory markers on PVT.</p> <p>Employing a two-sample MR framework, we merged genome-wide association study (GWAS) meta-analysis findings of 91 inflammation-associated proteins with independent PVT data from the FinnGen consortium's R10 release. A replication analysis was performed using a distinct GWAS dataset from the UK Biobank. Inverse variance weighting, MR-Egger regression, weighted median estimator, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier were used for analysis, supplemented by multivariable MR (MVMR) to adjust for cirrhosis effects.</p> <p>Findings indicate a significant inverse association between the genetically inferred concentration of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and PVT risk, evidenced by an odds ratio (OR) of 0.37 (95% confidence interval [CI]: 0.21–0.67; <i>p</i> = 9.2 × 10<sup>−4</sup>; adjusted for multiple testing <i>p</i> = 0.084). This association was corroborated in the replication phase (OR = 0.39, 95% CI: 0.17–0.93; <i>p</i> = 0.03) and through MVMR analysis (OR = 0.34, 95% CI: 0.15–0.79; <i>p</i> = 0.012). Sensitivity analyses disclosed no evidence of heterogeneity or pleiotropy.</p> <p>Our investigation emphasizes the 4E-BP1 as a protective factor against PVT, underscoring its potential relevance in understanding PVT pathogenesis and its implications for diagnosis and therapy.</p> ","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in thrombosis and hemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0044-1790259","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Portal vein thrombosis (PVT) is commonly encountered in patients with cirrhosis, challenging our understanding of its development, particularly the ambiguous contribution of inflammation. This study utilized Mendelian randomization (MR) to explore the causal impact of circulating inflammatory markers on PVT.

Employing a two-sample MR framework, we merged genome-wide association study (GWAS) meta-analysis findings of 91 inflammation-associated proteins with independent PVT data from the FinnGen consortium's R10 release. A replication analysis was performed using a distinct GWAS dataset from the UK Biobank. Inverse variance weighting, MR-Egger regression, weighted median estimator, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier were used for analysis, supplemented by multivariable MR (MVMR) to adjust for cirrhosis effects.

Findings indicate a significant inverse association between the genetically inferred concentration of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and PVT risk, evidenced by an odds ratio (OR) of 0.37 (95% confidence interval [CI]: 0.21–0.67; p = 9.2 × 10−4; adjusted for multiple testing p = 0.084). This association was corroborated in the replication phase (OR = 0.39, 95% CI: 0.17–0.93; p = 0.03) and through MVMR analysis (OR = 0.34, 95% CI: 0.15–0.79; p = 0.012). Sensitivity analyses disclosed no evidence of heterogeneity or pleiotropy.

Our investigation emphasizes the 4E-BP1 as a protective factor against PVT, underscoring its potential relevance in understanding PVT pathogenesis and its implications for diagnosis and therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
循环炎症蛋白与门静脉血栓的因果关系:孟德尔随机研究
门静脉血栓形成(PVT)在肝硬化患者中很常见,这对我们了解其发病过程,尤其是对炎症的模糊影响提出了挑战。本研究利用孟德尔随机化方法(MR)探讨了循环炎症标记物对门静脉血栓形成的因果影响。我们采用了双样本 MR 框架,将 91 个炎症相关蛋白的全基因组关联研究(GWAS)荟萃分析结果与芬兰基因联盟 R10 版本中的独立 PVT 数据进行了合并。利用英国生物库的一个不同的 GWAS 数据集进行了重复分析。分析中使用了反方差加权、MR-Egger 回归、加权中位数估计器和孟德尔随机多向性 RESidual Sum 和 Outlier,并辅以多变量 MR(MVMR)来调整肝硬化效应。研究结果表明,真核翻译起始因子 4E 结合蛋白 1(4E-BP1)的基因推断浓度与 PVT 风险之间存在明显的反向关联,其几率比(OR)为 0.37(95% 置信区间 [CI]:0.21-0.67;P<0.05):0.21-0.67;p = 9.2 × 10-4;多重测试调整后 p = 0.084)。这一关联在复制阶段(OR = 0.39,95% CI:0.17-0.93;p = 0.03)和 MVMR 分析(OR = 0.34,95% CI:0.15-0.79;p = 0.012)中得到证实。敏感性分析显示,没有证据表明存在异质性或多义性。我们的研究强调了 4E-BP1 作为 PVT 保护因子的作用,强调了它在了解 PVT 发病机制及其对诊断和治疗的影响方面的潜在相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in thrombosis and hemostasis
Seminars in thrombosis and hemostasis 医学-外周血管病
CiteScore
8.80
自引率
21.10%
发文量
132
审稿时长
6-12 weeks
期刊介绍: Seminars in Thrombosis and Hemostasis is a topic driven review journal that focuses on all issues relating to hemostatic and thrombotic disorders. As one of the premiere review journals in the field, Seminars in Thrombosis and Hemostasis serves as a comprehensive forum for important advances in clinical and laboratory diagnosis and therapeutic interventions. The journal also publishes peer reviewed original research papers. Seminars offers an informed perspective on today''s pivotal issues, including hemophilia A & B, thrombophilia, gene therapy, venous and arterial thrombosis, von Willebrand disease, vascular disorders and thromboembolic diseases. Attention is also given to the latest developments in pharmaceutical drugs along with treatment and current management techniques. The journal also frequently publishes sponsored supplements to further highlight emerging trends in the field.
期刊最新文献
Modulating Immune Responses: The Double-Edged Sword of Platelet CD40L. Thromboembolic Complications in Takotsubo Cardiomyopathy. Intravenous Direct Thrombin Inhibitors for Acute Venous Thromboembolism or Heparin-Induced Thrombocytopenia with Thrombosis in Children: A Systematic Review of the Literature. Thrombosis in Antiphospholipid Syndrome: Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies. Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1